Glaxosmithkline plc, of London, presented data at the American Thoracic Society meeting in San Diego, showing that the addition of umeclidinium (UMEC) at either dose to inhaled corticosteroid and long-acting beta2 agonist combination fluticasone proprionate and salmeterol (FSC) resulted in a statistically significant improvement in lung function when compared with placebo plus FSC in patients with chronic obstructive pulmonary disease over 12 weeks.